Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 129683, 5 pages
Research Article

Evaluation of Clinical Contributions Provided by Addition of the Brain, Calvarium, and Scalp to the Limited Whole Body Imaging Area in FDG-PET/CT Tumor Imaging

1Department of Nuclear Medicine, Faculty of Medicine, Dicle University, 21280 Diyarbakir, Turkey
2Department of Medical Oncology, Faculty of Medicine, Dicle University, 21280 Diyarbakir, Turkey
3Department of Nuclear Medicine, Faculty of Medicine, Izmir University, 35575 Izmir, Turkey
4Department of Nuclear Medicine, Elazig Training and Research Hospital, 23200 Elazig, Turkey

Received 17 February 2014; Accepted 28 May 2014; Published 16 June 2014

Academic Editor: David J. Yang

Copyright © 2014 Bekir Tasdemir et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Purpose. The aim of this study was to detect additional findings in whole body FDG-PET/CT scan including the brain, calvarium, and scalp (compared to starting from the base of the skull) in cancer patients and to determine contributions of these results to tumor staging and treatment protocols. Materials and Methods. We noted whether the findings related to the brain, calvarium, and scalp in 1359 patients had a potential to modify staging of the disease, chemotherapy protocol, radiotherapy protocol, and surgical management. We identified rates of metastatic findings on the brain, calvarium, and scalp according to the tumor types on FDG-PET/CT scanning. Results. We found FDG-PET/CT findings for malignancy above the base of the skull in 42 patients (3.1%), one of whom was a patient with an unknown primary tumor. Twenty-two of the metastatic findings were in the brain, 16 were in the calvarium, and two were in the scalp. Conclusion. This study has demonstrated that addition of the brain to the limited whole body FDG-PET/CT scanning may provide important contributions to the patient’s clinical management especially in patients with lung cancer, bladder cancer, malignant melanoma, breast cancer, stomach cancer, and unknown primary tumor.